Bio

Dr. Salmasi is a board-certified, fellowship-trained hematologist. She treats patients in the Hematology Program and the Hematologic Cancer Program at Stanford Health Care. Dr. Salmasi is the associate clinical chief for classical hematology. She is also a clinical associate professor in the Division of Hematology, Department of Medicine at Stanford University School of Medicine.

She treats a wide range of blood disorders and blood cancers. Her clinical/research interests include immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). Dr. Salmasi understands that patients need social and emotional support along with medical care. She founded the earliest adolescent and young adult survivorship support groups in Santa Cruz, California, and Toronto, Canada. Dr. Salmasi is also dedicated to training future doctors in providing excellent hematologic care.

Dr. Salmasi was the medical co-investigator for a national phase 3 clinical trial of endovascular therapy for treating chronic venous thrombosis.

Her research has appeared in the New England Journal of Medicine, Leukemia & Lymphoma journal and the Transfusion and Apheresis Science journal. Dr. Salmasi’s publications include articles and a chapter about lymphoma. She has also reviewed articles for the Biology of Blood and Marrow Transplantation journal and the Journal of Clinical Oncology.

Dr. Salmasi is a member of the American Society of Hematology.

Clinical Focus

  • Hematology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Hematology (2019)
  • Fellowship: University of Toronto Faculty of Medicine (2013) Canada
  • Residency: University of Toronto (2011) ON Canada
  • Medical Education: McMaster University Michael G. DeGroote School of Medicine (2007) Canada

Contact

  • Academic
    University - Academic staff Department: Medicine - Med/Hematology Position: Clinical Associate Professor
  • Clinical (Primary)  Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr Clinic F Breast Cancer Clinic Stanford, CA 94305 (650) 725-9113 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5156
  • Other Names:
    Giselle Salmasi

All Publications

  • More on Monoclonal Gammopathy of Thrombotic Significance. Reply. The New England journal of medicine Salmasi, G., Murray, D. L., Padmanabhan, A. 2024; 391 (15): 1464

    View details for DOI 10.1056/NEJMc2411324

    View details for PubMedID 39413391

  • Myeloma Therapy for Monoclonal Gammopathy of Thrombotic Significance. The New England journal of medicine Salmasi, G., Murray, D. L., Padmanabhan, A. 2024; 391 (6): 570-571

    View details for DOI 10.1056/NEJMc2406453

    View details for PubMedID 39115069

  • Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report. EJHaem Goyal, V., Salmasi, G., Leavitt, A. D., Rubenstein, J. L., Banerjee, R. 2022; 3 (3): 1000-1002

    Abstract

    Paraneoplastic coagulopathies are uncommon in patients with lymphoma. We report the first case of an acquired coagulopathy in a patient with isolated primary central nervous system lymphoma (PCNSL) demonstrating large-cell histology. In our patient, a paraneoplastic factor VII inhibitor significantly delayed a diagnostic lumbar puncture despite fresh frozen plasma and inactivated prothrombin complex concentrate. While her coagulopathy was effectively overcome with recombinant activated factor VIIa and subsequently with lymphoma-directed therapy, her delayed diagnosis likely contributed to a poor outcome. Our case highlights the importance of rapidly identifying and correcting paraneoplastic coagulopathies when PCNSL is suspected.

    View details for DOI 10.1002/jha2.482

    View details for PubMedID 36051043

    View details for PubMedCentralID PMC9421997

  • From cardiogenic shock to dual organ transplants: managing heparin-induced thrombocytopenia with therapeutic apheresis and IVIG ASAIO Journal Wu, Y., Baudart, S., Abad, A. J., Cheng, R., Salmasi, G., Klein, L. 2022
  • Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution Schoenbeck, K. L., Cerejo, M., Cornett, P. A., Damon, L. E., Gaensler, K. L., Leavitt, A. D., Logan, A. C., Mannis, G. N., Olin, R. L., Salmasi, G., Sayre, P. H., Shah, N. P., Dhruva, A., Atreya, C. E., Smith, C. C. AMER SOC HEMATOLOGY. 2019

    View details for DOI 10.1182/blood-2019-129638

    View details for Web of Science ID 000577164607248

  • Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms Schoenbeck, K. L., Salmasi, G., Cerejo, M., Cornett, P. A., Damon, L. E., Logan, A. C., Olin, R. L., Leavitt, A. D., Smith, C. C. AMER SOC HEMATOLOGY. 2019

    View details for DOI 10.1182/blood-2019-129705

    View details for Web of Science ID 000577160400245

  • Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leukemia & lymphoma Salmasi, G., Li, M., Sivabalasundaram, V., Panzarella, T., Tsang, R., Kukreti, V., Crump, M., Kuruvilla, J. 2015; 56 (6): 1659-64

    Abstract

    Rituximab is a monoclonal anti-CD20 antibody that is standard of care for treatment of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study was to quantify the incidence of rituximab (R)-related interstitial pneumonitis (IP) in patients with NHL receiving immunochemotherapy. All patients with NHL who received cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), R-CHOP or R-CVP in Princess Margaret Hospital between June 1998 and August 2009 were retrospectively reviewed. We compared cohorts of patients who did and did not receive R and documented the incidence of IP during and/or post-treatment. In total 560 patients were included in this analysis. The rate of IP in the entire cohort was 2.9% (16/560) with a trend toward a higher rate in the R group (3.95% vs. 1.3% [odds ratio 3.1, 0.84-17.27, p = 0.074]). Baseline pulmonary computed tomography abnormalities in patients with lymphoma are relatively common. The addition of R to chemotherapy does not significantly increase the risk of symptomatic chemotherapy-related IP.

    View details for DOI 10.3109/10428194.2014.963075

    View details for PubMedID 25356925

  • Trimming the fat with an IVIG approval process. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Chow, S., Salmasi, G., Callum, J. L., Lin, Y. 2012; 46 (3): 349-52

    View details for DOI 10.1016/j.transci.2012.03.030

    View details for PubMedID 22503308

  • Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta obstetricia et gynecologica Scandinavica Salmasi, G., Grady, R., Jones, J., McDonald, S. D. 2010; 89 (4): 423-441

    Abstract

    While active maternal tobacco smoking has well established adverse perinatal outcomes, the effects of passive maternal smoking, also called environmental tobacco exposure (ETS), are less well studied and less consistent.To determine to the effect of ETS on perinatal outcomes.Medline, EMBASE and reference lists were searched.Studies comparing ETS-exposed pregnant women with those unexposed which adequately addressed active maternal smoking.Two reviewers independently assessed titles, abstracts, full studies, extracted data and assessed quality. Dichotomous data were pooled using odds ratios (OR) and continuous data with weighted mean differences (WMD) using a random effects model.Seventy-six articles were included with a total of 48,439 ETS-exposed women and 90,918 unexposed women. ETS-exposed infants weighed less [WMD -60 g, 95% confidence interval (CI) -80 to -39 g], with a trend towards increased low birthweight (LBW, < 2,500 g; RR 1.16; 95% CI 0.99-1.36), although the duration of gestation and preterm delivery were similar (WMD 0.02 weeks, 95% CI -0.09 to 0.12 weeks and RR 1.07; 95% CI 0.93-1.22). ETS-exposed infants had longer infant lengths (1.75 cm; 95% CI 1.37-2.12 cm), increased risks of congenital anomalies (OR 1.17; 95% CI 1.03-1.34) and a trend towards smaller head circumferences (-0.11 cm; 95% CI -0.22 to 0.01 cm).ETS-exposed women have increased risks of infants with lower birthweight, congenital anomalies, longer lengths, and trends towards smaller head circumferences and LBW.

    View details for DOI 10.3109/00016340903505748

    View details for PubMedID 20085532

  • Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal fluid research Johnston, M., Zakharov, A., Papaiconomou, C., Salmasi, G., Armstrong, D. 2004; 1 (1): 2

    Abstract

    BACKGROUND: The parenchyma of the brain does not contain lymphatics. Consequently, it has been assumed that arachnoid projections into the cranial venous system are responsible for cerebrospinal fluid (CSF) absorption. However, recent quantitative and qualitative evidence in sheep suggest that nasal lymphatics have the major role in CSF transport. Nonetheless, the applicability of this concept to other species, especially to humans has never been clarified. The purpose of this study was to compare the CSF and nasal lymph associations in human and non-human primates with those observed in other mammalian species. METHODS: Studies were performed in sheep, pigs, rabbits, rats, mice, monkeys and humans. Immediately after sacrifice (or up to 7 hours after death in humans), yellow Microfil was injected into the CSF compartment. The heads were cut in a sagittal plane. RESULTS: In the seven species examined, Microfil was observed primarily in the subarachnoid space around the olfactory bulbs and cribriform plate. The contrast agent followed the olfactory nerves and entered extensive lymphatic networks in the submucosa associated with the olfactory and respiratory epithelium. This is the first direct evidence of the association between the CSF and nasal lymph compartments in humans. CONCLUSIONS: The fact that the pattern of Microfil distribution was similar in all species tested, suggested that CSF absorption into nasal lymphatics is a characteristic feature of all mammals including humans. It is tempting to speculate that some disorders of the CSF system (hydrocephalus and idiopathic intracranial hypertension for example) may relate either directly or indirectly to a lymphatic CSF absorption deficit.

    View details for DOI 10.1186/1743-8454-1-2

    View details for PubMedID 15679948

    View details for PubMedCentralID PMC546409